Maryland is currently home to 2676 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904
Recruiting
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/24/2025
Locations: Ep0162 50093, Baltimore, Maryland
Conditions: Stereotypical Prolonged Seizures
Register for Updates
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
NCT05063162
Recruiting
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/24/2025
Locations: Mog001 50552, Baltimore, Maryland
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Register for Updates
Chronic Pain in Rheumatoid Arthritis
NCT05038553
Recruiting
The objective is to identify modifiable clinical factors and neurobiological pathways that lead to the development of chronic pain in patients with early rheumatoid arthritis. Participants will undergo quantitative sensory testing, a type of testing that involves assessing response to well-defined, quantifiable painful stimuli, at 0, 3, and 12 months. A subset of participants will also undergo magnetic resonance imaging at 0 and 12 months to assess neuroimaging markers that have previously been... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Arthritis, Rheumatoid, Pain
Register for Updates
A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases
NCT05035420
Recruiting
Background: The COVID-19 outbreak has strained the health care system. New tools are needed for diagnostic testing and monitoring of people who have the virus. Researchers want to test a device they hope can screen, detect, and monitor symptoms linked to respiratory diseases like COVID-19. Objective: To evaluate and validate a device that measures breathing, body temperature, heart rate, and tissue oxygenation. Eligibility: Healthy adults ages 18 and older with no flu-like symptoms and no c... Read More
Gender:
ALL
Ages:
Between 18 years and 78 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: COVID-19, Upper Respiratory Infection, Lower Respiratory Infection
Register for Updates
Combination Therapy for the Treatment of Diffuse Midline Gliomas
NCT05009992
Recruiting
This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. ONC201, panobinostat, and paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some of the enzymes needed for cell growth. This phas... Read More
Gender:
ALL
Ages:
Between 2 years and 39 years
Trial Updated:
04/24/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Register for Updates
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT04924075
Recruiting
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutif... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/24/2025
Locations: Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site, Baltimore, Maryland
Conditions: Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
Register for Updates
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586
Recruiting
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/24/2025
Locations: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Conditions: Primary Mediastinal Large B-Cell Lymphoma
Register for Updates
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
NCT04305054
Recruiting
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn: * About the safety and how well people tolerate pembrolizumab given with other treatments * How many people have melanoma that responds (gets smaller or goes away) to trea... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/24/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022), Baltimore, Maryland
Conditions: Melanoma
Register for Updates
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
NCT03882034
Recruiting
Background: For children with gigantism, too much growth hormone (GH) in the body causes abnormal growth and many other problems. Current treatments often don t work; no medical treatment is approved by FDA. Researchers want to see if the drug pegvisomant can help. Objective: To test the role of pegvisomant in children and adolescents with gigantism. Eligibility: People ages 2-18 with GH excess for whom usual treatments have not worked or who are not eliginle for them Design: Participants... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pituitary Disease
Register for Updates
Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers
NCT03878121
Recruiting
Background: Researchers want see if three new HIV (human immunodeficiency virus) vaccines are safe. Two vaccines are carried by live adenoviruses, which are natural and typically cause cold symptoms or an eye infection. Researchers want to see if all the vaccines help fight HIV and if the adenoviruses are contagious. Objectives: To test the safety and effects of three new HIV vaccines. Eligibility: Healthy adults 18 49 years old (vaccinees) Their household and intimate contacts 18 65 years... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer
Register for Updates
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
NCT03831958
Recruiting
Background: The pituitary gland produces hormones. A tumor in this gland can cause it to produce too much of the hormone cortisol. Too much cortisol in the body causes Cushing disease. This disease causes many problems. Some of these problems might persist after the disease is cured. Objective: To find out the long-term effects of exposure to high levels of cortisol during childhood and adolescence. Eligibility: People ages 10-42years who were diagnosed with Cushing disease before age 21 an... Read More
Gender:
ALL
Ages:
Between 2 years and 90 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cushing Disease
Register for Updates
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: MedStar Franklin Square Medical Center ( Site 0046), Baltimore, Maryland
Conditions: Solid Tumors, Hematologic Malignancies
Register for Updates